-Reuters
Immatics Biotechnologies Granted U.S. Patent #11498948 Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
https://www.scribd.com/document/607726122/IMTX-Patent
Related Posts
Oppenheimer Initiates Coverage On UserTesting with Outperform Rating, Announces Price Target of $14
Oppenheimer analyst Brian Schwartz initiates coverage on UserTesting (NYSE:USER) with a Outperform rating and announces Price Target of $14.
$10 Trillion Asset Manager BlackRock To Offer Crypto Trading: Report
The world’s largest asset manager BlackRock, Inc. (NYSE: BLK) is reportedly preparing to launch a cryptocurrency trading service for investors.
Truist Securities Maintains Buy on New Relic, Lowers Price Target to $80
Truist Securities analyst Joel Fishbein maintains New Relic (NYSE:NEWR) with a Buy and lowers the price target from $85 to $80.